Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.
Divisions of Hematology-Oncology, and Hematopathology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Center Ave., Suite. 572, Pittsburgh, PA 15232, USA.
Frank
F
Lieberman
Victor
V
Yazbeck
Anastasios
A
Raptis
Raymond
R
Felgar
Michael
M
Boyiadzis
D000328:Adult; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000473:pathology; D002493:Central Nervous System Diseases / Q000150:complications / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000175:diagnosis / Q000209:etiology*; D008279:Magnetic Resonance Imaging; D051757:PAX5 Transcription Factor / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism; D012269:Ribosomal Proteins / Q000378:metabolism; D014184:Transplantation, Homologous / Q000009:adverse effects
D019394:Ki-67 Antigen; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; D016601:RNA-Binding Proteins; D012269:Ribosomal Proteins; C067169:RPL22 protein, human